Mesothelin targeted cancer immunotherapy for patients

• Project/Area Number: 18K15295
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: National Defense Medical College
• Principal Investigator: Einama Takahiro 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究施設、病院並びに防衛, 外科学, 講師 (70421964)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Project Status: Completed (Fiscal Year 2021)
• Budget Amount: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000); Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2018: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
• Keywords: Mesothelin / 膵癌 / 抗体治療 / CA125

Outline of Final Research Achievements

Our aim was to proceed Mesothelin targeted immunotherapy.
We showed that mesothelin antibody made cell to cell adhesions lost their function and increased chemotherapy effect for mesothelin positive cells.
And we have reported that mesothelin and CA125 co-expression existed in pancreatic cancer, IPMN, breast cancer, biriary tract cancer and cervical cancer.

Academic Significance and Societal Importance of the Research Achievements

Mesothelinは膵癌、肺癌、卵巣癌などの難治性癌に多く発生しており、抗Mesothelin治療を行うことでこれらの難治性癌の予後が延長する可能性がある。
本研究成果は動物実験において証明され、さらに人への応用される可能性のあるものである。

Research Products

• [Journal Article] Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells (2021)
  • Author(s): Matsuzawa Fumihiko、Kamachi Hirofumi、Mizukami Tatsuzo、Einama Takahiro、Kawamata Futoshi、Fujii Yuki、Fukai Moto、Kobayashi Nozomi、Hatanaka Yutaka、Taketomi Akinobu
  • Journal Title: BMC Cancer Volume: 21 Issue: 1
  • DOI: 10.1186/s12885-020-07722-3
  • Peer Reviewed / Open Access
• [Journal Article] Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma (2021)
  • Author(s): Takihata Yasuhiro、Einama Takahiro、Kobayashi Kazuki、Suzuki Takafumi、Yonamine Naoto、Fujinuma Ibuki、Tsunenari Takazumi、Yamagishi Yoji、Iwasaki Toshimitsu、Miyata Yoichi、Shinto Eiji、Ogata Sho、Tsujimoto Hironori、Ueno Hideki、Kishi Yoji
  • Journal Title: Oncology Letters Volume: 21 Issue: 5
  • DOI: 10.3892/ol.2021.12675
  • Peer Reviewed / Open Access
• [Journal Article] Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients (2021)
  • Author(s): Einama Takahiro、Yamagishi Yoji、Takihata Yasuhiro、Suzuki Takafumi、Kobayashi Kazuki、Yonamine Naoto、Fujinuma Ibuki、Tsunenari Takazumi、Koga Makiko、Nagata Ken、Shiraishi Takehiro、Nakazawa Akiko、Shinto Eijii, Ueno Hideki、Kishi Yoji、Tsuda Hitoshi
  • Journal Title: Biomarker Research Volume: 9 Issue: 1
  • DOI: 10.1186/s40364-021-00335-3
  • Peer Reviewed / Open Access
• [Journal Article] Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal?type breast cancer (2020)
  • Author(s): Suzuki Takafumi、Yamagishi Yoji、Einama Takahiro、Koiwai Tomomi、Yamasaki Tamio?、Fukumura?koga Makiko、Ishibashi Yusuke、Takihata Yasuhiro?、Shiraishi Takehiro、Miyata Yoichi、Iwasaki Toshimitsu、Shinto Eiji、Sato Kimiya?、Ueno Hideki、Yamamoto Junji、Kishi Yoji、Tsuda Hitoshi
  • Journal Title: Oncology Letters Volume: 20 Issue: 5 Pages: 193-193
  • DOI: 10.3892/ol.2020.12055
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer. (2019)
  • Author(s): Takehiro Shiraishi, Eiji Shinto, Satsuki Mochizuki, Hitoshi Tsuda, Yoshiki Kajiwara, Koichi Okamoto, Takahiro Einama, Kazuo Hase, Hideki Ueno
  • Journal Title: Virchows Arch Volume: 474 Issue: 3 Pages: 297-307
  • DOI: 10.1007/s00428-018-02514-4
  • Peer Reviewed / Open Access / Int'l Joint Research